Glucagon-like peptide-1 (GLP-1) receptor agonists—widely prescribed for type 2 diabetes and obesity—may carry a small but clinically important safety signal, according to research from Rutgers University. The study links these drugs to an increased risk of ischemic optic neuropathy, a rare condition in which reduced blood flow to the optic nerve can cause sudden vision loss.
The investigation, published in Annals of Internal Medicine, used real-world health data from a large cohort of U.S. adults aged 18 to 65 diagnosed with type 2 diabetes. The researchers focused on people who started GLP-1 therapy, including commonly used agents such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and analyzed outcomes consistent with ischemic optic neuropathy.
Ischemic optic neuropathy occurs when the optic nerve’s blood supply is impaired, leading to abrupt changes in vision. Clinically, this often presents as blurring, dimming, or loss of part of the visual field in one eye rather than total blindness, and it can be permanent—particularly for the non-arteritic anterior form, which accounts for most reported cases.
Although the absolute event rate is low, the study estimated that the risk increase corresponded to roughly three to four additional cases per 10,000 patients treated with GLP-1s over 18 months. “Rare” does not mean “irrelevant,” the authors note, because sudden vision loss can be irreversible and may require urgent specialist assessment.
The researchers emphasize that the findings describe an association rather than proof of causation. Differences in baseline health among patients initiating GLP-1 treatment could partly explain the signal. Even so, the growing use of GLP-1 therapies in both diabetic and non-diabetic populations heightens the importance of vigilant medication safety monitoring.
Lead author Chintan Dave, a pharmacy and pharmacoepidemiology researcher at Rutgers, added that patients who develop symptoms should not wait. Early recognition of visual changes and prompt ophthalmologic evaluation may be especially crucial for those with higher baseline risk.
The study also suggests demographic patterns: many reported cases occurred among men or among men and women aged 50 to 65. That detail could help clinicians identify who may benefit from heightened counseling or faster response when visual symptoms appear.
Future work is needed to determine whether GLP-1 exposure directly contributes to ischemic optic neuropathy or whether unmeasured factors are driving the observed association. For now, the overall risk remains low, but the authors argue that patients and clinicians should be aware of the potential.
Subject of Research: People
Article Title: Glucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy: A Target Trial Emulation
News Publication Date: 14-Jul-2026
Web References: https://www.acpjournals.org/doi/10.7326/ANNALS-25-00860
References: 10.7326/ANNALS-25-00860
Image Credits:
Keywords: GLP-1, ischemic optic neuropathy, type 2 diabetes, obesity, sudden vision loss, semaglutide, tirzepatide
Tags: clinical implications of GLP-1 therapy risksGLP-1 receptor agonistsischemic optic neuropathy risklong-term safety of GLP-1 receptor agonistsobesity drug safetyophthalmic side effects of diabetes medicationsrare adverse effects of GLP-1 drugsreal-world health data studiessemaglutide and tirzepatide safetytype 2 diabetes managementvision loss in diabetes patientsvisual field loss associated with diabetes drugs
